[Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma].
To assess the value of multi-tumor markers protein biochip in the diagnosis and therapy of pulmonary carcinoma. Twelve tumor markers (CA199, NSE, CEA, CA242, Ferrtin, β-HCG, AFP, f-PSA, PSA, CA125, HGH, and CA153) were detected using protein chip in 308 patients with pulmonary carcinoma, 218 with benign lung lesions and 250 healthy subjects. The positivity rate was 72.4% in pulmonary carcinoma cases, obviously higher than that in the benign cases (22.0%, P<0.01) and healthy subjects (5.6%, P<0.01). The positivity rates differed significantly between the pulmonary carcinoma cases of different pathological types. The positivity rates of CEA, CA125, and CA153 were significantly higher in adenocarcinoma cases than in squamous carcinoma cases (P<0.05), and also higher in cases with lymph node metastasis than in those without (71.9% vs 52.1%, P<0.05). Protein biochip containing multiple tumor markers provides valuable assistance in the diagnosis and therapeutic effect monitoring of pulmonary carcinoma.